Therapeia Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 26-07-2024
- Paid Up Capital ₹ 0.10 M
as on 26-07-2024
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Ebitda
- Net Worth -4.34%
(FY 2023)
- Total Assets -3.21%
(FY 2023)
About Therapeia Biosciences
The Corporate was formerly known as Pilani Exim Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sachin Patel, Vinay Bhomia, and Mamta Bhomia serve as directors at the Company.
- CIN/LLPIN
U74994GJ2018PTC103568
- Company No.
103568
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Aug 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Therapeia Biosciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sachin Patel  | Director | 28-Sep-2019 | Current |
| Vinay Bhomia | Director | 08-Aug-2018 | Current |
| Mamta Bhomia | Director | 08-Aug-2018 | Current |
Financial Performance of Therapeia Biosciences.
Therapeia Biosciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth dipped by a decrease of 4.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Therapeia Biosciences?
In 2023, Therapeia Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sanjivani Super Speciality Hospitals Private LimitedActive 16 years 7 monthsVinay Bhomia and Mamta Bhomia are mutual person
- Shravan Chemopharma Private LimitedActive 5 years 9 months
Vinay Bhomia and Mamta Bhomia are mutual person
- Shyam Exotica Private LimitedActive 12 years 4 months
Vinay Bhomia and Mamta Bhomia are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Therapeia Biosciences?
Unlock and access historical data on people associated with Therapeia Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Therapeia Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Therapeia Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
